MedTrace Logo

Efficacy of Changing to TRAVATAN® From Prior Therapy

NCT01493427 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2014-05-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.

Conditions

Interventions

DRUG

Travoprost 0.004%

Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Severine Durier, Pharm.D · Alcon Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-02-28
Completion
2013-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01493427 on ClinicalTrials.gov